Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK

International Journal of Infectious Diseases

Volumn 14, Issue 8, 2010, Pages

  Melzer, Mark ^a   Gupta, Nidhi ^a   Petersen, Irene ^b   Cook, Sue ^c   Hall, Bridget ^a  

^a QUEEN S HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Drug resistance; NICE; Past treatment; TB

Indexed keywords

AMINOGLYCOSIDE; ISONIAZID; QUINOLONE; RIFAMPICIN; BACTERIAL PROTEIN; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL ASSESSMENT; DEMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; GENOTYPE; HUMAN; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; NEWBORN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; UNITED KINGDOM; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; CLASSIFICATION; DRUG EFFECTS; EVALUATION STUDY; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; PRESCHOOL CHILD; PROCEDURES; STATISTICAL MODEL; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; LONDON; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 77954957701     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.02.2247     Document Type: Article

References (37)

1. Donaldson L. Stopping tuberculosis in England. An action plan from the Chief Medical Officer. London: Department of Health; October 2004. Available at: (accessed on 10/01/2010). http://www.dh.gov.uk/.
2. Kruijshaar M.E., Watson J.M., Drobniewski F., Anderson C., Brown T.J., Magee J.G. Increasing antituberculosis drug resistance in the United Kingdom: analysis of national surveillance data. BMJ 2008, 336:1231-1234.
3. Anderson C, Moore J, Kruijshaar M, Abubakar I. Tuberculosis in the UK. Annual report on tuberculosis surveillance in the UK 2008. (accessed on 31/5/2010). http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1224268885463.
4. Breathnach A.S., de Ruiter A., Holdsworth G.M., Bateman N.T., O'Sullivan D.G., Rees P.J. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect 1998, 39:111-117.
5. Ormerod P. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998, 53:536-548. Chair of Joint Tuberculosis Committee of British Thoracic Society.
6. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., et al. Detection of rifampicin-resistant mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
7. Melzer M., Brown T.J., French G.L., Dickens A., McHugh T.D., Bagg L.R. Molecular analysis of drug resistant TB. Thorax 2002, 57:562-563.
8. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2006. Available at: (accessed on 10/01/2010). http://www.nice.org.uk/CG033.
9. Health Protection Agency, 2008. Available at: (accessed on 10/01/2010). http://www.hpa.org.uk/.
10. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
11. Zignol M., Hosseini M.S., Wright A., Weezenbeck C.L., Nunn P., Watt C.J. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479-485.
12. Falzon D., Infuso A., Ait-Belghiti F. In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. Int J Tuberc Lung Dis 2006, 10:954-958.
13. Wright A., Zignol M., Van Deun A., Falzon D., Gerdes S.R., Feldman K. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009, 373:1861-1873.
14. Collins C.H., Grange J.M., Yates M.D. Tuberculosis bacteriology: organization and practice 1997, Butterworth-Heinemann, Oxford, UK.
15. Lietooghe R., Michiels N., Habib S., Moran M.B., Muynck A. Perception and social consequences of tuberculosis, a focus group study of tuberculosis patients in Sialkot, Pakistan. Soc Sci Med 1995, 41:1685-1692.
16. al Jarad N., Parastatides S., Paul E.A., Sheldon CD., Gaya H., Rudd R.M. Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992. Thorax 1994, 49:808-810.
17. Djuretic T., Herbert J., Drobniewski F., Yates M., Smith E.G., Magee J.G. Antibiotic resistant tuberculosis in the United Kingdom 1993-1999. Thorax 2002, 57:477-482.
18. Conaty S.J., Hayward A.C., Story A., Glynn J.R., Drobniewski F.A., Watson J.M. Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiol Infect 2004, 132:1099-1108.
19. Pritchard A.J., Hayward A.C., Monk P.N., Neal K.R. Risk factors for drug resistant tuberculosis in Leicestershire-poor adherence to treatment remains an important cause of resistance. Epidemiol Infect 2003, 130:481-483.
20. Augustynowicz-Kopec E., Zwolska Z., Jaworski A., Kostrzewa E., Klatt M., Swidersk A. Frequency of drug resistant tuberculosis in Poland in 2000 as compared to 1997. Pneumonol Alergol Pol 2002, 70:193-202.
21. Helbling P., Altpeter E., Raeber P.A., Pfyffer G.E., Zellweger J.P. Surveillance of antituberculosis drug resistance in Switzerland 1995-1997: the central link. Eur Respir J 2000, 16:200-202.
22. Robert J., Trystram D., Truffot-Pernot C., Carbonnelle B., Grosset J. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. Int J Tuberc Lung Dis 2000, 4:665-672.
23. Ruddy M., Balabanova Y., Graham C., Fedorin I., Malomanova N., Elisarova E. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region. Russia. Thorax 2005, 60:130-135.
24. Clark C.M., Li J., Driver C.R., Munsiff S.S. Risk factors for drug-resistant tuberculosis among non-US born persons in New York City. Int J Tuberc Lung Dis 2005, 9:964-969.
25. Moniruzzaman A., Elwood R.K., Schulzer M., Fitzgerald J.M. Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia. Int J Tuberc Lung Dis 2006, 10:844-850.
26. Baumann M.H., Nolan R., Petrini M., Lee Y.C., Light R.W., Schneider E. Pleural tuberculosis in the United States: incidence and drug resistance. Chest 2007, 131:1125-1132.
27. Phyu S., Lwin T., Ti T., Maung W., Mar W.W., Shein S.S. Drug-resistant tuberculosis in Yangon, Myanmar. Scand J Infect Dis 2005, 37:846-851.
28. Dhingra V.K., Rajpal S., Bhalla P., Yadav A., Jain S.K., Hanif M. Prevalence of initial drug resistance to M. tuberculosis in new sputum positive RNTCP patients. J Commun Dis 2003, 35:82-89.
29. Paramasivan C.N., Venkataraman P., Chandrasekaran V., Bhat S., Narayanan P.R. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Dis 2002, 6:479-484.
30. Santha T., Thomas A., Chandrasekaran V., Selvakumar N., Gopi P.G., Subramani R. Initial drug susceptibility profile of M. tuberculosis among patients under TB programme in South India. Int J Tuberc Lung Dis 2006, 10:52-57.
31. Cox H.S., Orozco J.D., Male R., Ruesch-Gerdes S., Falzon D., Small I. Multidrug-resistant tuberculosis in central Asia. Emerg Infect Dis 2004, 10:865-872.
32. Araj G.F., Saade M., Itani L.Y. Nationwide study of drug resistance among acid-fast bacilli positive pulmonary tuberculosis cases in Lebanon. Int J Tuberc Lung Dis 2006, 10:63-67.
33. Wilkinson D., Pillay M., Davies G.R., Sturm A.W. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Trans R Soc Trop Med Hyg 1996, 90:692-695.
34. Githui W.A., Juma E.S., Van Gorkom J., Kibuga D., Odhianbo J., Drobniewski F. Antituberculosis drug resistance surveillance in Kenya, 1995. Int J Tuberc Lung Dis 1998, 2:499-505.
35. Githui W.A., Hawken M.P., Juma E.S., Godfrey-Faussett P., Swai O.B., Kibuga D.K. Surveillance of drug-resistant tuberculosis and molecular evaluation of transmission of resistant strains in refugee and non-refugee populations in North-Eastern Kenya. Int J Tuberc Lung Dis 2000, 4:947-955.
36. Maguire H., Dale J.W., McHugh T.D., Butcher P.D., Gillespie S.H., Costetsos A. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax 2002, 57:617-622.
37. Ruddy M.C., Davies A.P., Yates M.D., Yates S., Balasegaram S., Drabu Y. Outbreak of isoniazid resistant tuberculosis in north London. Thorax 2004, 59:279-285.